Randomized double-blind trial shows sitagliptin lowers mealtime glucose without affecting gastric emptying in type 2 diabetes, indicating drug efficacy depends on baseline digestion rate.
Aims To determine the effects of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, on gastric emptying (GE) of a high‐carbohydrate meal and associated glycaemic and blood pressure (BP) responses in type 2 diabetes mellitus (T2DM). Materials and Methods Fourteen patients with T2DM (nine men, five women; age 67.8 ± 1.5 years; body mass index 31.2 ± 0.9 kg/m 2 ; T2DM duration: 4.2 ± 0.9 years; glycated haemoglobin: 46 ± 1.8 mmol/mol [6.4% ± 0.2%]), managed by diet and/or metformin, underwent concurrent measurements of GE, BP and plasma glucose for 240 minutes after ingestion of a radiolabelled mashed potato meal after receiving sitagliptin (100 mg) or placebo in randomized, double‐blind, crossover fashion on 2 consecutive days. Results Sitagliptin reduced postprandial plasma glucose ( P < .005) without affecting GE ( P = .88). The magnitude of the glucose‐lowering effect (change in incremental area under the curve 0–240 min from placebo to sitagliptin) was related to GE (kcal/min) on placebo ( r = 0.68, P = .008) There was a comparable fall in systolic BP ( P = .80) following the meal, with no difference between the 2 days. Conclusions In T2DM, while sitagliptin has no effect on either GE or postprandial BP, its ability to lower postprandial glucose are dependent on the basal rate of GE.
No takes yet. Share an insight, caveat, or question.
Stevens et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: